Inrebic

A drug used to treat adults with primary myelofibrosis (MF) or secondary MF, including post-polycythemia vera MF and post-essential thrombocythemia MF. It is used in patients whose disease is intermediate or high risk. It is also being studied in the treatment of other conditions. Inrebic blocks a protein called JAK2, which may help keep abnormal blood cells or cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called fedratinib hydrochloride.